中药联合标准西药治疗玫瑰痤疮的系统评价与Meta分析
本研究系统检索并纳入13项RCT(N=1348),比较中药联合标准西药与常规抗玫瑰痤疮治疗。结果显示联合治疗在临床症状评分、中医证候评分、DLQI、EI、IL-37及总有效率、复发率方面均更优,但证据质量较低,需谨慎解读。
要点
- 中药联合标准西药可降低玫瑰痤疮临床症状与中医证候评分。
- 联合治疗改善DLQI、红斑指数及IL-37水平,并提高总有效率、降低复发率。
- 因纳入研究质量低且证据不确定,结论需谨慎用于临床决策。
核心结论
- 中药联合标准西药治疗玫瑰痤疮在多项评分及有效率、复发率上优于常规抗玫瑰痤疮治疗。
- 因证据不确定且研究报告质量低,上述结果需谨慎解读。
研究设计与样本
- 系统评价与Meta分析,PROSPERO注册号CRD42023472737。
- 检索PubMed、Embase、Web of Science、CNKI、万方、CBM、维普,截至2023年9月,不限语言。
- 纳入13项RCT,共1348例玫瑰痤疮患者。
- 采用随机效应模型合并数据。
主要发现
- 临床症状评分平均降低-2.24%[95%CI(-3.02至-1.46),p<0.00001]。
- 中医证候评分降低-4.42[95%CI(-5.33至-3.50),p<0.00001]。
- DLQI评分降低-2.55[95%CI(-3.73至-1.36),p<0.00001]。
- EI降低-151.97[95%CI(-276.59至-27.36),p<0.00001]。
- IL-37降低-4.23[95%CI(-4.95至-3.51),p=0.854];总有效率RR=1.25[95%CI(1.18,1.32),p=0.994];复发率=0.27[95%CI(0.15,0.46),p=0.297]。
关键数值与推荐
- 主要结局包括临床症状评分、中医证候评分、DLQI、EI及IL-37水平。
- 联合治疗对比常规抗玫瑰痤疮治疗的合并效应值如上所列。
临床怎么用
- 在标准西药治疗基础上联合中药可能改善玫瑰痤疮症状、生活质量及复发情况。
- 临床决策时应结合患者具体情况,并注意证据质量较低的局限性。
局限性
- 纳入研究证据不确定且报告质量低,结论需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A combination of standard biomedical treatment and traditional Chinese medicine (TCM) has been suggested as a therapeutic approach for rosacea that may significantly lower the recurrence rate and clinical symptom scores. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the impact of this combination treatment on clinical symptom and TCM syndrome scores, as well as on the scores of the Dermatology Life Quality Index (DLQI), erythema index (EI), and interleukin 37 (IL-37) levels in patients with rosacea. METHODS: The PROSPERO registration number for the study is CRD42023472737. We systematically searched the PubMed, Embase, Web of Science, China National Knowledge Infrastructure Wanfang Database, China Biomedical Medicine database (CBM), and the VIP information resource integration service platform (cqvip) databases for RCTs (published from the beginning to September 2023, regardless of the language used) that compared the traditional Chinese medicine and standard biomedical treatment combination treatment to conventional anti-rosacea treatments. Our primary outcomes comprised the clinical symptom and TCM syndrome scores, and the scores of Dermatology Life Quality Index, erythema index, and IL-37 levels. We used a random-effects model to evaluate the pooled data. RESULTS: We identified 260 studies. Of these, 13 eligible studies were employed for analysis (N = 1,348 participants). Compared with other anti-rosacea treatments, the TCM and standard biomedical treatment combination treatment yielded an improved mean reduction in the clinical symptom score -2.24% [95% CI (-3.02 to -1.46), p < 0.00001], TCM syndrome score -4.42 [95% CI (-5.33 to -3.50), p < 0.00001], and the score of DLQI of -2.55 [95% CI (-3.73 to -1.36), p < 0.00001], EI of -151.97 [95% CI (-276.59 to -27.36), p < 0.00001], and IL-37 level -4.23 [95% CI (-4.95 to -3.51), p = 0.854], as well as in the overall effective rate risk ratio (RR) = 1.25 [95%CI (1.18, 1.32), p = 0.994] and the recurrence rate = 0.27 [95%CI (0.15, 0.46), p = 0.297]. CONCLUSION: The TCM and standard biomedical treatment combination treatment can provide a better outcome, including a reduction in the TCM syndrome and clinical symptom scores, and in the scores of DLQI, EI, and IL-37. Hence, this combination is a viable and more effective therapeutic approach for rosacea. However, these results should be considered cautiously because of uncertain evidence and the low quality of the study reports considered in this meta-analysis. SYSTEMATIC REVIEW REGISTRATION: website, identifier CRD42023472737.
引用
- Yu R, Li S, Yang Y, et al. Combination of traditional Chinese medicine and standard biomedical treatment for rosacea: a systematic review and a meta-analysis. Front Pharmacol. 2024. PMID: 39175550. doi:10.3389/fphar.2024.1397141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。